Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Buchtitelbild

2017 | OriginalPaper | Buchkapitel

1. Current Status and Characteristics of Cancer

verfasst von : Tao Feng, Yanli Zhao

Erschienen in: Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Cancer is among the most deadly diseases known, with 13 million new cancer cases and about 8 million casualties worldwide each year. This chapter introduces the current status and causes of cancer, and the characteristics of cancer tissues including abnormal metabolism, abnormal vasculature, resistance to anti-proliferative growth factors (GFs), unlimited replicative potential, immune system activation and inflammation, and interstitial pressure.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Nächstes Kapitel Clinical Anticancer Drugs for Cancer Treatment
Literatur
Bergers G, Benjamin LE (2003) Angiogenesis: tumourigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410CrossRef
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRef
Coppedè F, Lopomo A, Spisni R, Migliore L (2014) Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20:943–956CrossRef
De la Rica R, Aili D, Stevens MM (2012) Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 64:967–978CrossRef
Dudley AC (2012) Tumor endothelial cells. Cold Spring Harb Perspect Med 2:a006536CrossRef
Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am J Pathol 162:1747–1757CrossRef
Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 63:136–151CrossRef
Ganapathy-Kanniappan S, Geschwind JFH (2013) Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 12:152CrossRef
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nat Rev Cancer 4:891–899CrossRef
Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11:1133–1146CrossRef
Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9:1144–1155CrossRef
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–679CrossRef
Hesketh R (2013) Introduction in cancer biology: a concise journey from epidemiology through cell and molecular biology to treatment and prospects. Cambridge University Press, New York
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Dalton WS (2008) Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7:1780–1794CrossRef
Koontongkaew S (2013) The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 4:66–83CrossRef
Maeda H, Wua J, Sawaa T, Matsumurab Y, Horic K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284CrossRef
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
Michener CM, Ardekani AM, Petricoin EF, Liotta LA, Kohn EC (2002) Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 26:249–255CrossRef
Munn LL (2003) Aberrant vascular architecture in tumours and its importance in drug-based therapies. Drug Discov Today 8:396–403CrossRef
Narang AS, Varia S (2011) Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 63:640–658CrossRef
Ng JMK, Yu J (2015) Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 16:2472–2496CrossRef
Shuker DEG (2007) Socioeconomic and molecular basis of cancer. In: Missailidis S (ed) The cancer clock. Wiley, Chichester, pp 3–24
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9–29CrossRef
Siemann DW (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 37:63–74CrossRef
Spencer DS, Puranik AS, Peppas NA (2015) Intelligent nanoparticles for advanced drug delivery in cancer treatment. Curr Opin Chem Eng 7:84–92CrossRef
Stubbs JM, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6:15–19CrossRef
Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–135CrossRef
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef
Wakefield LM, Yang Y, Dukhanina O (2000) Transforming growth factor-β and breast cancer: lessons learned from genetically altered mouse models. Breast Cancer Res 2:100–106CrossRef
Metadaten
Titel
Current Status and Characteristics of Cancer
verfasst von
Tao Feng
Yanli Zhao
Copyright-Jahr
2017
Verlag
Springer Singapore
Buch
Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy

Print ISBN: 978-981-10-3297-4

Electronic ISBN: 978-981-10-3299-8

Copyright-Jahr: 2017

DOI
https://doi.org/10.1007/978-981-10-3299-8_1

Neuer Inhalt

    Bildnachweise